🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the effort against drug-resistant strains of the bacteria, according to scientists.

An International Public Health Issue

Gonorrhoea infections are on the rise worldwide, with data suggesting more than 82 million infections annually. Notably increased rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely step in the face of rising global incidence, escalating drug resistance and the highly restricted therapeutic options at this time.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The global health body has designated it as a "high-priority threat". A tracking program showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Approval

One new antibiotic, alternatively called a brand name, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Scientists hope that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This drug, which is also used to treat UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation GARDP collaborated with the drug firm Innoviva to see it through.

“This milestone signifies a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Research Study Outcomes and Worldwide Availability

According to findings detailed in a major medical journal, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the typical regimen, which uses two antibiotics. The research included nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the ability to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have voiced hope. The availability of a easy-to-administer therapy such as this is hailed as a "critical tool" for managing the epidemic. This is deemed essential to reduce the burden of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea worldwide.